Imperial College London

DrSanjayPopat

Faculty of MedicineNational Heart & Lung Institute

Reader in Cancer Medicine
 
 
 
//

Contact

 

+44 (0)20 7808 2132s.popat Website

 
 
//

Location

 

Royal Marsden HospitalThe Royal Marsden Hospital

//

Summary

 

Publications

Publication Type
Year
to

510 results found

Lindsay CR, Shaw EC, Moore DA, Rassl D, Jamal-Hanjani M, Steele N, Naheed S, Dick C, Taylor F, Adderley H, Black F, Summers Y, Evans M, Rice A, Fabre A, Wallace WA, Nicholson S, Haragan A, Taniere P, Nicholson AG, Laing G, Cave J, Forster MD, Blackhall F, Gosney J, Popat S, Kerr KMet al., 2021, Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists, BRITISH JOURNAL OF CANCER, ISSN: 0007-0920

Journal article

Cookson W, Nastase A, Mandal A, Lu SK, Abunathan H, Morris-Rosendahl D, Zhand YZ, Sun X-M, Gennatas S, Rintoul R, Edwards M, Bowman A, Chernova T, Benepal T, Lim E, Newman Taylor A, Nicholson A, Popat S, Willis A, MacFarlane M, Lathrop M, Bowcock A, Moffatt Met al., 2021, Integrated genomics point to immune vulnerabilities in pleural mesothelioma, Scientific Reports, ISSN: 2045-2322

Journal article

Popat S, Liu G, Lu S, Song G, Ma X, Yang JC-Het al., 2021, Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3), FUTURE ONCOLOGY, ISSN: 1479-6694

Journal article

Cui W, Popat S, 2021, Pleural mesothelioma (PM) - The status of systemic therapy., Cancer Treat Rev, Vol: 100

Pleural mesothelioma (PM) remains a malignancy with poor prognosis. Despite initial disappointing response rates to single-agent chemotherapy, upfront platinum and anti-folate-based combination chemotherapy has remained the backbone of treatment for PM for the last three decades. The role of maintenance chemotherapy remains unclear; switch-maintenance gemcitabine has shown improvements in progression-free but not overall survival. The addition of antiangiogenic agents to chemotherapy yielded modest improvements in survival, both upfront in combination with platinum-pemetrexed, and in the relapsed setting. Immunotherapy, particularly PD-(L)1 inhibitors, has shown important but variable effectiveness in relapsed PM when used as monotherapy, and is an important salvage treatment after first-line chemotherapy. Furthermore, the randomized phase 3 trial of ipilimumab-nivolumab versus platinum-pemetrexed chemotherapy demonstrated improved overall survival favouring ipilimumab-nivolumab (HR 0.74, 96.6% CI 0.60-0.91; p = 0.0020), establishing this regimen as the new standard first-line treatment for PM, particularly in those with non-epithelioid histology. Increased interest in PM genomics has led to development of novel personalized therapeutics, such as those targeting DNA repair and EZH2 pathways, however with variable outcomes in trials. Targeting the membrane glycoprotein mesothelin and arginine deprivation are other important strategies under ongoing investigation. The field of PM is changing and new treatments bring hope to a largely lethal and poor prognostic malignancy. Despite these developments, current challenges include understanding the role of combination and multimodality treatments, drivers of resistance to treatment, and establishing predictive biomarkers to improve patient selection and treatment sequencing.

Journal article

Tomasik B, Bienkowski M, Braun M, Popat S, Dziadziuszko Ret al., 2021, Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score >= 2-Systematic review and meta-analysis, LUNG CANCER, Vol: 158, Pages: 97-106, ISSN: 0169-5002

Journal article

Domingo-Sabugo C, Willis-Owen SAG, Mandal A, Nastase A, Dwyer S, Brambilla C, Gálvez JH, Zhuang Q, Popat S, Eveleigh R, Munter M, Lim E, Nicholson AG, Lathrop M, Cookson WOC, Moffatt MFet al., 2021, Distinct pancreatic and neuronal Lung Carcinoid molecular subtypes revealed by integrative omic analysis

<jats:title>Summary</jats:title><jats:p>Lung Carcinoids (L-CDs) are uncommon low-grade neuroendocrine tumours that are only recently becoming characterised at the molecular level. Notably data on the molecular events that precipitate altered gene expression programmes are very limited. Here we have identified two discrete L-CD subtypes from transcriptomic and whole-genome DNA methylation data, and comprehensively defined their molecular profiles using Whole-Exome Sequencing (WES) and Single Nucleotide Polymorphism (SNP) genotyping. Subtype (Group) 1 features upregulation of neuronal markers (L-CD-NeU) and is characterised by focal spindle cell morphology, peripheral location (71%), high mutational load (<jats:italic>P</jats:italic>=3.4×10<jats:sup>−4</jats:sup>), recurrent copy number alterations and is enriched for Atypical Lung Carcinoids. Group 2 (L-CD-PanC) are centrally located and feature upregulation of pancreatic and metabolic pathway genes concordant with promoter hypomethylation of beta cell and genes related to insulin secretion (<jats:italic>P</jats:italic>&lt;1×10<jats:sup>−6</jats:sup>). L-CD-NeU tumours harbour mutations in chromatin remodelling and in SWI/SNF complex members, while L-CD-PanC tumours show aflatoxin mutational signatures and significant DNA methylation loss genome-wide, particularly enriched in repetitive elements (<jats:italic>P</jats:italic>&lt;2.2 × 10<jats:sup>−16</jats:sup>). Our findings provide novel insights into the distinct mechanisms of epigenetic dysregulation in these lung malignancies, potentially opening new avenues for biomarker selection and treatment in L-CD patients.</jats:p>

Journal article

Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, Helland A, Hochmair M, Perol M, Bent-Ennakhil N, Kruhl C, Novello Set al., 2021, Real-world treatment outcomes with brigatinib in patients with pretreated ALK plus metastatic non-small cell lung cancer, LUNG CANCER, Vol: 157, Pages: 9-16, ISSN: 0169-5002

Journal article

Miura S, Hsia T-C, Hung J-Y, Jung HA, Shih J-Y, Yang T-Y, Park C-K, Lee SH, Okamoto T, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Maerten A, Popat Set al., 2021, UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations., Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472

Conference paper

Willis-Owen S, Domingo Sabugo C, Starren E, Liang L, Freidin M, Arseneault M, Zhang Y, Kiong Lu S, Popat S, Lim E, Nicholson A, Riazalhosseini Y, Lathrop M, Cookson W, Moffatt Met al., 2021, Y disruption, autosomal hypomethylation and poor male lung cancer survival, Scientific Reports, Vol: 11, ISSN: 2045-2322

Lung cancer is the most frequent cause of cancer death worldwide. It affects more men than women, and men generally have worse survival outcomes. We compared gene co-expression networks in affected and unaffected lung tissue from 126 consecutive patients with Stage IA–IV lung cancer undergoing surgery with curative intent. We observed marked degradation of a sex-associated transcription network in tumour tissue. This disturbance, detected in 27.7% of male tumours in the discovery dataset and 27.3% of male tumours in a further 123-sample replication dataset, was coincident with partial losses of the Y chromosome and extensive autosomal DNA hypomethylation. Central to this network was the epigenetic modifier and regulator of sexually dimorphic gene expression, KDM5D. After accounting for prognostic and epidemiological covariates including stage and histology, male patients with tumour KDM5D deficiency showed a significantly increased risk of death (Hazard Ratio [HR] 3.80, 95% CI 1.40–10.3, P = 0.009). KDM5D deficiency was confirmed as a negative prognostic indicator in a further 1100 male lung tumours (HR 1.67, 95% CI 1.4–2.0, P = 1.2 × 10–10). Our findings identify tumour deficiency of KDM5D as a prognostic marker and credible mechanism underlying sex disparity in lung cancer.

Journal article

Cui W, Popat S, 2021, Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma, DRUGS, Vol: 81, Pages: 971-984, ISSN: 0012-6667

Journal article

Milner-Watts C, Lyons H, Cui W, Yousaf N, Minchom A, Bhosle J, Davidson M, Scott S, Faull I, Nagy R, O'Brien M, Popat Set al., 2021, Detection of tier 1 variants with circulating tumour (ct) DNA next generation sequencing (NGS) in UK non-small cell lung cancer (NSCLC) patients, Publisher: ELSEVIER IRELAND LTD, Pages: S28-S28, ISSN: 0169-5002

Conference paper

Ly F, Brambilla C, Rice A, Jan L, MacMahon S, Thompson L, Antoniou G, Popat S, Nicholson Aet al., 2021, An audit of compliance with NOLCP in the GLH era, Publisher: ELSEVIER IRELAND LTD, Pages: S27-S27, ISSN: 0169-5002

Conference paper

Clark J, Murphy R, Dell E, Julve M, Januszewski A, Popat S, Newsom-Davis Tet al., 2021, Pleomorphic lung carcinoma - a rare response to a rare tumour, Publisher: ELSEVIER IRELAND LTD, Pages: S76-S76, ISSN: 0169-5002

Conference paper

Sandsund C, Cowan-Dickie S, Fautly A, Tocka N, Angelis V, Yousaf N, Popat Set al., 2021, Treatment dose-delay due to an exercise induced creatinine kinase level elevation/raise in a man with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (aNSCLC) - a case report, Publisher: ELSEVIER IRELAND LTD, Pages: S75-S75, ISSN: 0169-5002

Conference paper

McDonald F, Guckenberger M, Popat S, Faivre-Finn C, Andratschke N, Riddell A, Hanna G, Prakash V, Nair A, Diez P, Patel P, Kilburn L, Toms C, Bliss Jet al., 2021, HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours, Publisher: ELSEVIER IRELAND LTD, Pages: S70-S71, ISSN: 0169-5002

Conference paper

Joshi K, Muhith A, Obeid M, Milner-Watts C, Yousaf N, Popat S, Davidson M, Bhosle J, O'Brien M, Minchom Aet al., 2021, Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond, LUNG CANCER, Vol: 156, Pages: 147-150, ISSN: 0169-5002

Journal article

Passaro A, Mok T, Peters S, Popat S, Ahn M-J, de Marinis Fet al., 2021, Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations, JOURNAL OF THORACIC ONCOLOGY, Vol: 16, Pages: 764-773, ISSN: 1556-0864

Journal article

Garcia Campelo MR, Lin HM, Zhu Y, Perol M, Jahanzeb M, Popat S, Zhang P, Camidge DRet al., 2021, Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK plus non-small cell lung cancer (ALTA-1L), LUNG CANCER, Vol: 155, Pages: 68-77, ISSN: 0169-5002

Journal article

Anaissie J, Popat S, Mayer WA, Taylor JMet al., 2021, Innovative Approaches to Battling Resident Burnout in a Urology Residency Program, UROLOGY PRACTICE, Vol: 8, Pages: 387-392, ISSN: 2352-0779

Journal article

Manickavasagar T, Yuan W, Carreira S, Gurel B, Miranda S, Ferreira A, Crespo M, Riisnaes R, Baker C, O'Brien M, Bhosle J, Popat S, Banerji U, Lopez J, de Bono J, Minchom Aet al., 2021, HER3 expression and MEK activation in non-small-cell lung carcinoma, LUNG CANCER MANAGEMENT, Vol: 10, ISSN: 1758-1966

Journal article

Bischoff H, Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak A, Fujimoto N, Peters S, Tsao A, Mans-Field A, Popat S, Sun X, Padilla B, Aanur P, Daumont M, Bennett B, McKenna M, Baas Pet al., 2021, First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743, Publisher: GEORG THIEME VERLAG KG, Pages: S17-S17, ISSN: 0934-8387

Conference paper

Cui W, Milner-Watts C, Saith S, Bhosle J, Minchom AR, Davidson M, Page S, Locke I, Yousaf N, Popat S, O'Brien MERet al., 2021, Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19, Publisher: ELSEVIER SCIENCE INC, Pages: S795-S795, ISSN: 1556-0864

Conference paper

Miura S, Hsia T-C, Hung J-Y, Jung HA, Shih J-Y, Yang T-Y, Park C-K, Lee SH, Okamoto T, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Maerten A, Popat Set al., 2021, UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, Publisher: ELSEVIER SCIENCE INC, Pages: S776-S777, ISSN: 1556-0864

Conference paper

Cui W, Milner-Watts C, Lyons H, Yousaf N, Minchom AR, Bhosle J, Davidson M, Scott S, Faull I, Nagy RJ, O'Brien MER, Popat Set al., 2021, Circulating tumour (ct) DNA next generation sequencing (NGS) in UK advanced non-small cell lung cancer (aNSCLC) patients (pts), Publisher: ELSEVIER SCIENCE INC, Pages: S787-S788, ISSN: 1556-0864

Conference paper

Collins DC, Sundar R, Constantinidou A, Dolling D, Yap TA, Popat S, O'Brien ME, Banerji U, de Bono JS, Lopez JS, Tunariu N, Minchom Aet al., 2021, Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease (vol 20, 1210, 2020), BMC Cancer, Vol: 21, Pages: 1-1, ISSN: 1471-2407

Journal article

Besse B, Felip E, Kim ES, Clifford C, Louie-Gao M, Yagui-Beltran A, Popat Set al., 2021, AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC, Publisher: ELSEVIER SCIENCE INC, Pages: S684-S684, ISSN: 1556-0864

Conference paper

Borghaei H, Besse B, Bardia A, Mazieres J, Popat S, Augustine B, D'Amelio A, Barrios D, Rugo Het al., 2021, Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study, Publisher: ELSEVIER SCIENCE INC, Pages: S236-S236, ISSN: 1556-0864

Conference paper

Whisenant J, Wong S, Torri V, Revuelta J, Halmos B, Ceresoli G, Monnet I, Popat S, Arrieta O, Azab M, Dingemans A, Spasic J, Van Meerbeeck J, Recondo G, Reinmuth N, Valter A, Unk M, Ghalehtaki R, Steinfort D, Chorostowska-Wynimko J, Viola L, Horn L, Peters S, Wakelee HA, Garassino MC, Tapan Uet al., 2021, COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT), Publisher: ELSEVIER SCIENCE INC, Pages: S297-S297, ISSN: 1556-0864

Conference paper

Popat S, 2021, Immunotherapy - Current State of Play (Concentrating on Current Data for First Line and Salvage Strategies), Publisher: ELSEVIER SCIENCE INC, Pages: S84-S84, ISSN: 1556-0864

Conference paper

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00557130&limit=30&person=true